Mark H. O’Hara

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Adham S. Bear, Robert H. Vonderheide, Mark H. O’Hara|Cancer Cell|2020

Cited by 665Open Access

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

Gregory L. Beatty, Mark H. O’Hara, Simon F. Lacey et al.|Gastroenterology|2018

Cited by 499Open Access

Hepatocytes direct the formation of a pro-metastatic niche in the liver

Jae W. Lee, Meredith L. Stone, Paige M. Porrett et al.|Nature|2019

Cited by 421Open Access

An NK-like CAR T cell transition in CAR T cell dysfunction

Charly R. Good, M. Ángela Aznar, Shunichiro Kuramitsu et al.|Cell|2021

Cited by 395Open Access

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers

Andrew R. Haas, János L. Tanyi, Mark H. O’Hara et al.|Molecular Therapy|2019

Cited by 369Open Access

CART-meso without cyclophosphamide. The best overall response was stable disease (11/15 patients). CART-meso cells expanded in the blood and reached peak levels by days 6-14 but persisted transiently. Cyclophosphamide pre-treatment enhanced CART-meso expansion but did not improve persistence beyond 28 days. CART-meso DNA was detected in 7/10 tumor biopsies. Human anti-chimeric antibodies (HACA) were detected in the blood of 8/14 patients. CART-meso cells were well tolerated and expanded in the blood of all patients but showed limited clinical activity. Studies evaluating a fully human anti-mesothelin CAR are ongoing.

Is this you? Claim your profile.

Top publicationsby citations